DDW Protocol Variation and Lower Limits

Jump to any DDW page

• DDW Overview — what DDW is, why it matters, and how to use this section

• Evidence by Cancer Type — where the human and preclinical signals are strongest

• DDW and Pancreatic Cancer — the clearest tumour-specific human study and its limits

• DDW Protocol Variation and Lower Limits — why experts differ on how low to go

• DDW Sourcing and Brand Options — how to think about brands, ppm options, mixing, and buying strategy

DDW protocols are not fully standardised.

That matters because readers will see different expert recommendations on how low to go.

The main disagreement is not about whether lowering deuterium may pressure cancer metabolism.

The disagreement is about how deep depletion should go before healthy-tissue trade-offs become a concern.

Important note on DDW expert protocol variations

In Petra Devalaar's interview transcript, she describes a more conservative lower limit than the deeper Somlyai-style step-downs.

In plain terms, her view is:

• some advanced-cancer patients may benefit from lowering to around 80 ppm

• she is cautious about pushing much lower

• the main reason is her concern that very deep depletion could compromise the glycocalyx

That is the core protocol difference this page is addressing.

Why this question comes up

The published DDW oncology literature often uses a step-down model.

In practice, that usually means starting around 105 or 85 ppm and then moving lower over time.

Some published cancer protocols then continue to 65 ppm and sometimes 45 ppm.

That approach is most closely associated with Gábor Somlyai's work.

The Somlyai-style model

The Somlyai framework treats DDW as a sustained metabolic intervention.

The logic is that deeper and prolonged deuterium depletion may increase metabolic stress on tumour cells that already have unstable mitochondrial and redox handling.

That is why published Somlyai-linked oncology papers often use a lower-ppm step-down rather than stopping at a modest reduction.

The best-known pancreatic study followed that pattern.

Patients started at 85 ppm and later stepped down to 65 ppm and 45 ppm while receiving chemotherapy.

The more conservative floor

Some clinicians prefer not to go as low.

Petra Devalaar has described a more conservative lower limit of about 80 ppm in advanced cancer.

Her concern is not that deuterium is beneficial for cancer.

Her concern is that very deep systemic depletion may also affect healthy structured-water systems.

The structure she highlights is the glycocalyx.

The glycocalyx theory

The glycocalyx is a carbohydrate-rich surface layer lining cells and blood vessels.

It helps regulate barrier function, mechanosensing, immune traffic, and cell-environment signalling.

What the glycocalyx is

It is not a minor surface detail.

It is a continuous nano-layer of sugar-coated proteins and lipids lining cells, arteries, veins, and tissues throughout the body.

In practical terms, it acts like a living interface between the cell and its environment.

That means it helps control:

• what enters and leaves the cell surface

• how flow forces are sensed

• how immune cells recognise tissues

• how vascular permeability is regulated

Devalaar's explanation adds one further layer.

Her view is that the glycocalyx is partly organised around structured water, which is why deuterium becomes relevant.

In cancer biology, the glycocalyx matters because tumour cells often remodel it in ways that support invasion and immune evasion.

Devalaar's argument goes one step further.

Her view is that healthy glycocalyx structure may depend partly on the physical behaviour of structured water, and that excessively deep deuterium depletion could impair that architecture.

This is the core reason she gives for preferring an ~80 ppm floor rather than pushing lower in all patients.

How deuterium is being interpreted in this model

Devalaar's framework distinguishes between three locations where excess deuterium may matter:

• the mitochondrial matrix

• the cytoplasm

• the glycocalyx

The first two fit the standard DDW story more closely.

Too much deuterium is thought to impair mitochondrial energy handling and disturb broader metabolic control.

The glycocalyx is the more nuanced part.

Her argument is not simply that lower is always better.

Her argument is that the glycocalyx may need a baseline level of deuterium to help maintain the physical integrity of its structured-water layer.

In that interpretation:

• too much deuterium may thicken, stiffen, or distort the layer

• too little deuterium may weaken the structural support healthy glycocalyx depends on

That is why she frames the target as a balance problem rather than a pure depletion problem.

Why ~80 ppm is her lower limit

This is the clinical point behind the whole debate.

Devalaar is not arguing that deuterium is favourable for cancer.

She is arguing that healthy tissue may still require some deuterium for structural purposes, especially in the glycocalyx.

Her practical interpretation is:

• below about 80 ppm, depletion may start affecting healthy glycocalyx integrity

• that could increase vascular leakiness and impair immune-cell trafficking

• it could worsen the cellular environment even while applying anticancer metabolic pressure

That is why she appears more comfortable in a rough 80 to 125 ppm range than with more aggressive depletion in all patients.

Why the theory is interesting

This idea is biologically interesting for three reasons.

• the glycocalyx is real and clinically important

• cancer cells do alter glycocalyx thickness and composition

• water structure and isotope effects are central to the broader DDW rationale

So the theory is not random.

It fits the wider idea that deuterium biology is not just about mitochondria.

The glycocalyx as cancer's armour

One reason this theory feels compelling is that the glycocalyx already matters in cancer for another reason.

Cancer cells often remodel their glycocalyx into a thicker, denser, and more protective surface layer.

That altered glycocalyx can help tumour cells:

• evade immune recognition

• resist close immune-cell contact

• alter signalling with surrounding tissue

• support invasion and progression

So there are really two glycocalyx questions here at once:

• how to reduce or normalise the pathological tumour glycocalyx

• how to preserve the healthy vascular and tissue glycocalyx

That is exactly where Devalaar places her caution.

Hypersialylation and immune evasion

One of the main mechanisms behind the cancer glycocalyx is hypersialylation.

That means cancer cells load their surface with excess sialic-acid-rich glycans.

This can create both:

• a physical barrier that makes immune-cell contact harder

• an immune-silencing signal through Siglec-family inhibitory receptors

This is one reason researchers now talk about glyco-immune checkpoints alongside better-known checkpoint systems such as PD-1 / PD-L1.

Tumour progression link

An abnormally thickened glycocalyx does not only affect immune escape.

It can also alter how tumour cells interact with the surrounding matrix.

That may help with:

• invasion

• resistance to mechanical pressure

• altered growth signalling

• metastatic behaviour

So when Devalaar argues for caution around going too low, the logic is not that the cancer glycocalyx should be preserved.

It is that the healthy glycocalyx may need protection even while the pathological tumour glycocalyx is being pushed in a more normal direction.

Why this connects back to the 80 ppm floor

This is the most elegant part of the argument.

If DDW helps normalise the water structure and signalling environment of the cancer glycocalyx, that could be useful.

But if depletion is pushed too far systemically, the same intervention might also start degrading healthy vascular and tissue glycocalyx.

That would create a trade-off:

• possible downward pressure on the tumour's abnormal glycocalyx

• possible damage to healthy barrier and signalling structures

This is why Devalaar appears to place the balance point at about 80 ppm rather than automatically following deeper Somlyai-style step-downs in every case.

What remains unproven

This is the key calibration point.

The glycocalyx-based lower-limit argument remains a hypothesis-level interpretation, not an established clinical rule.

At present, there is no comparative human trial showing that:

• stopping at 80 ppm preserves glycocalyx function better than 65 ppm

• deeper depletion below 80 ppm worsens outcomes

• one lower-limit target is broadly optimal across cancer types

So this should be read as an expert protocol debate, not as settled fact.

How to interpret the disagreement

The fairest summary is:

• Somlyai-style approach: deeper depletion may apply stronger anticancer metabolic pressure

• Devalaar-style caution: deeper depletion may also increase risk of unwanted effects in healthy tissue

• current evidence gap: no high-quality trial has resolved where the best lower limit sits

This means protocol intensity should not be treated as a simple more-is-better scale.

Practical takeaways

What is well supported

• DDW is best understood as an investigational metabolic adjunct

• published oncology protocols usually use gradual step-downs

• the pancreatic study used 85 → 65 → 45 ppm alongside chemotherapy

• protocol design likely matters, not just DDW use in the abstract

What is plausible but not settled

• deeper depletion may increase tumour-cell stress

• very low ppm targets may not suit every patient equally

• healthy-tissue structures such as the glycocalyx may be part of the reason some clinicians stop higher

• tumour glycocalyx biology may be one reason DDW affects more than mitochondria alone

What should not be overstated

• that 80 ppm is a proven universal safe floor

• that 65 ppm or 45 ppm are automatically too low

• that the glycocalyx theory has already been clinically validated

• that speculative glycocalyx interpretations have already been resolved in human trials

Bottom line

The lower-limit debate is one of the most important unresolved questions in DDW protocol design.

It is reasonable to say that experts differ on how low to go.

It is also reasonable to say that the best lower limit remains clinically unsettled.

For now, the most evidence-matched position is to treat this as a real protocol variation with a plausible biological rationale, but incomplete proof.

Key References

Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC8204545/

Deuterium-Depleted Water in Cancer Therapy: A Systematic Review
https://pmc.ncbi.nlm.nih.gov/articles/PMC11085166/

Anticancer Effect of Deuterium Depleted Water - Redox Disbalance Leads to Oxidative Stress
https://pmc.ncbi.nlm.nih.gov/articles/PMC6885702/

Cancer Glycocalyx and Its Significance in Cancer Progression
https://pmc.ncbi.nlm.nih.gov/articles/PMC7039198/

Targeting the Glycocalyx in Cancer and the Tumour Microenvironment
https://pmc.ncbi.nlm.nih.gov/articles/PMC9655334/

Cancer Glycocalyx Mediates Cancer Progression and Therapy Resistance
https://pmc.ncbi.nlm.nih.gov/articles/PMC7039198/

MIT glyocalyx manuscript by Stephanie Seneff
https://people.csail.mit.edu/seneff/2025/glycocalyx.pdf

Jump to any DDW page

• DDW Overview — what DDW is, why it matters, and how to use this section

• Evidence by Cancer Type — where the human and preclinical signals are strongest

• DDW and Pancreatic Cancer — the clearest tumour-specific human study and its limits

• DDW Protocol Variation and Lower Limits — why experts differ on how low to go

• DDW Sourcing and Brand Options — how to think about brands, ppm options, mixing, and buying strategy